P2Y12 Inhibitors: Plavix® (Clopidogrel), Effient® (Prasugrel),
Ticlid® (Ticlopidine)
Every year, approximately 29 million prescriptions1 , including over 6.5 million new prescriptions, are written for Plavix, making it the second largest selling drug with over $9.1 billion in sales worldwide.2
Studies have shown that up to 1 in 3 patients may not respond adequately to antiplatelet therapies such as P2Y12 inhibitors (e.g. clopidogrel (Plavix))3 due to numerous factors:
• Genetic differences (e.g. CYP2C19)
FDA and the makers of Plavix warned that the effectiveness of Plavix
may be reduced in some patients.4
• Concomitant medications (e.g. proton pump inhibitors)
• Pre-existing health conditions (e.g. diabetes, impaired renal function, obesity)
• Non-compliance
Patients who do not respond adequately to their antiplatelet therapies may be at significantly greater risk of ischemic events and death.5-8 Additionally, powerful new therapies such as prasugrel (Effient) are now available to help combat ischemic events, but may put patients at a greater risk of bleeding.9
In minutes, the VerifyNow® P2Y12 Test can help physicians determine patient platelet response to P2Y12 inhibitors such as Plavix, Effient and Ticlid.